APN - Aspen - Finalisation Of Term Loan Funding Facility

APN - Aspen - Finalisation Of Term Loan Funding Facility                        
ASPEN PHARMACARE HOLDINGS LIMITED                                               
(Incorporated in the Republic of South Africa)                                  
Registration number 1985/0002935/06                                             
Share code:  APN                                                                
ISIN:  ZAE000066692                                                             
("Aspen" or "the Company")                                                      
Finalisation of term loan funding facility                                      
Shareholders are advised that Aspen Global Incorporated ("Aspen Global"), a     
wholly owned subsidiary of Aspen Pharmacare Holdings Ltd, has concluded a five- 
year US Dollar denominated funding arrangement for an amount of USD 385 million 
with a consortium of banks.  This funding has replaced a bridging loan from the 
Standard Group which was raised primarily to settle Aspen Global`s liability of 
GBP 170 million to GlaxoSmithKline ("GSK") arising from the acquisition of four 
branded products from GSK.                                                      
The funding arrangement which was executed on 10 October 2008, comprises of:    
-    A 5-year amortising loan of USD 255 million, with a 1-year capital         
    repayment holiday                                                           
-    A 5-year non-amortising loan of USD 130 million.  Repayments may be made on
this loan out of free cash flow.                                            
The cost of this debt has been fixed at an all in rate of 6,11% per annum over  
90%of its term  (which takes account of prepayments) by Aspen Global entering   
into an interest rate swap transaction as follows:                              
-    100% cover of interest payments over the first 3 years of the loans        
-    83% cover of interest payments over the 4th year of the loans              
-    66% cover of interest payments over the 5th year of the loans.             
The interest payments remaining unhedged, bear interest at a rate of 3-month USD
LIBOR plus a margin of 2,8%.                                                    
The above arrangements are considered to be favourable, given current global    
financial markets.                                                              
Sponsor:                                                                        
Investec Bank Limited                                                           
15 October 2008                                                                 
Date: 16/10/2008 07:05:03 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.